Autolus Therapeutics (AUTL) Change in Cash (2018 - 2025)

Autolus Therapeutics (AUTL) has reported Change in Cash for 8 consecutive years, with $18.0 million the latest figure, recorded in Q4 2025.

• Quarterly Change in Cash rose 104.19% year-over-year to $18.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$123.2 million (down 968.26% YoY) and the FY2025 annual result came in at -$123.2 million, down 968.26% from the prior year.
• Change in Cash improved to $18.0 million in Q4 2025 per AUTL's latest filing, from -$37.7 million in the prior quarter.
• Over the last five years, Change in Cash for AUTL reached as high as $519.2 million in Q1 2024 and fell as low as -$429.7 million in Q4 2024.
• A 5-year average of -$2.4 million and a median of -$38.6 million in 2023 frame the typical range for Change in Cash.
• The largest YoY upside for Change in Cash was 1417.59% in 2024 against a maximum downside of 2502.23% in 2024.
• Year by year, Change in Cash stood at $137.4 million in 2021, then jumped by 59.67% to $219.4 million in 2022, then sank by 107.53% to -$16.5 million in 2023, then tumbled by 2502.23% to -$429.7 million in 2024, then jumped by 104.19% to $18.0 million in 2025.
• According to Business Quant data, Change in Cash over the past three periods registered $18.0 million, -$37.7 million, and $28.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.